# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Voltaire (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN002-SYN-TD
- Date: 1778-04-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Honorine Delacroix-Mensah, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review of the resection pathology and a trial without catheter; decision on treatment. **S**

## History of present illness

Voltaire returns a week after the transurethral resection and two days after the sick visit for a catheter-associated infection. He has been afebrile since yesterday morning on cefpodoxime, and the culture grew Escherichia coli sensitive to it. The urine is pale pink without clots. Since the resection he has had a burning ache above the pubic bone and bladder spasms, worst in the evening, rated 5 of 10; acetaminophen when he remembers takes the edge off. He asked for something strong, saying that a friend has offered him drops made with opium. He has had no constipation on polyethylene glycol. The trial without catheter began this morning: the catheter was removed at 8 am and he voided 260 mL before this visit. He came with his assistant and wants to hear the results plainly and to decide today. **S**

| Element | Detail |
|---|---|
| Pathology | Keratinizing squamous cell carcinoma invading the muscularis propria, with lymphovascular invasion; no urothelial component or carcinoma in situ |
| Infection | Afebrile on day 3 of cefpodoxime; Escherichia coli sensitive |
| Pain | Suprapubic burning and evening spasm, 5 of 10 |
| Voiding trial | Catheter out this morning; voided 260 mL; residual 140 mL |
| IPSS | 14 (moderate), from 22 before the catheter |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired after the infection; no fever since yesterday morning; appetite small |
| Genitourinary | Positive | Pale pink urine, frequency, burning, and evening spasm after resection; no clots |
| Gastrointestinal | Negative | Bowels open daily |
| Musculoskeletal | Negative | No bone pain |
| Psychiatric | Positive | Shaken by the diagnosis but composed; wants to keep working |

5 systems reviewed. **S**

## Current medications

- Tamsulosin 0.4 mg oral capsule, one capsule at bedtime **S**
- Polyethylene glycol 3350, 17 g in a glass of water once daily **S**
- Cefpodoxime 200 mg oral tablet, one tablet by mouth twice daily for 7 days **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth three times daily (3 g a day) **S**
- Oxycodone 5 mg oral tablet, one half tablet (2.5 mg) by mouth every 6 hours if needed for bladder pain not relieved by acetaminophen, no more than three doses a day; 15 tablets dispensed **S**
- Sennosides 8.6 mg oral tablet, two tablets at bedtime while taking oxycodone **S**
- Naloxone 4 mg nasal spray, one spray in one nostril for suspected opioid overdose; call 911; may repeat in 2 to 3 minutes in the other nostril **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/68 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.9 °C; oxygen saturation 96% on room air; weight 53.4 kg; BMI 18.5 kg/m². All vital signs are synthetic.

Hemoglobin: 10.9 g/dL (low); White blood cells: 8.2 10*3/uL; Platelets: 254 10*3/uL; Potassium: 4.5 mmol/L; Creatinine: 1.22 mg/dL; eGFR: 59 mL/min/1.73 m² (low); Post-void residual (bladder scan): 140 mL (high); IPSS: 14; Pain score: 5. All results are synthetic.

## Change since baseline

- Hemoglobin: 11.6 g/dL (low) at baseline, 10.9 g/dL (low) at this visit **S**
- White blood cells: 7.8 10*3/uL at baseline, 8.2 10*3/uL at this visit **S**
- Platelets: 268 10*3/uL at baseline, 254 10*3/uL at this visit **S**
- Potassium: 5 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Creatinine: 1.68 mg/dL (high) at baseline, 1.22 mg/dL at this visit **S**
- eGFR: 40 mL/min/1.73 m² (low) at baseline, 59 mL/min/1.73 m² (low) at this visit **S**
- Post-void residual (bladder scan): 460 mL (high) at baseline, 140 mL (high) at this visit **S**
- IPSS: 22 at baseline, 14 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin, alert, and engaged; temperature 36.9 C |
| Cardiovascular | Blood pressure 124/68 mmHg; heart rate 82, regular |
| Abdomen | Mild suprapubic tenderness; bladder not palpable after voiding; no masses |
| Lymph nodes | No inguinal or supraclavicular nodes |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Squamous cell carcinoma of the bladder, muscle-invasive** (C67.4). Keratinizing squamous cell carcinoma of the posterior wall and dome, invading muscle, with lymphovascular invasion and a mobile palpable mass under anesthesia; with the CT urography and clear chest CT, clinical stage cT3b N0 M0 (stage IIIA). Pure squamous cell carcinoma is uncommon outside regions where schistosomiasis is common; it responds less well to chemotherapy than urothelial carcinoma, and radical cystectomy offers the best chance of cure. The G8 screen is 11 of 17 (abnormal), with low weight, reduced mobility, and help needed for shopping and travel, though he is independent in self-care and thinking clearly; his creatinine is 1.22 mg/dL (eGFR 59). We discussed four paths in plain terms: radical cystectomy with an ileal conduit, with a substantial risk of complications and a long recovery at his age; daily radiotherapy over four weeks with bladder preservation; weekly palliative radiotherapy (36 Gy in six fractions) aimed at controlling bleeding and local symptoms with few visits; and symptom care alone. His goals are to stay at home, finish his play, and avoid long hospital stays, and he accepts that weekly radiotherapy is unlikely to cure the cancer. **S**
   - He chose weekly hypofractionated radiotherapy, 36 Gy in six fractions; the radiation oncology team will plan it next week.
   - The palliative care team will join his care now, alongside treatment.
   - Dr. Bergström-Nwosu agrees with the plan and will see him if bleeding, clots, or retention return.
2. **Visible blood in the urine with difficult urination** (R31.0). Explained by the bladder cancer, with an enlarged prostate and chronic retention; superseded by those diagnoses. **S**
   - Managed under the bladder cancer, retention, and prostate problems.
3. **Chronic urinary retention** (R33.8). Trial without catheter passed: voided 260 mL with a post-void residual of 140 mL on tamsulosin. IPSS 14. **S**
   - Continue tamsulosin.
   - Bladder scan at the next visit; teach him to watch for a falling stream, overflow, or pain.
4. **Catheter-associated urinary tract infection** (T83.511A). Improving on day 3 of cefpodoxime; organism sensitive; white count 8.2. **S**
   - Complete seven days.
5. **Chronic constipation** (K59.09). Regular now; an opioid would worsen it. **S**
   - Add senna two tablets at night with any oxycodone; continue polyethylene glycol.
6. **Pain from the bladder cancer and resection**. Suprapubic burning and spasm, 5 of 10, interfering with his evening work. Acetaminophen has been taken irregularly. He has no history of a substance use disorder or overdose, but he has long dosed himself with remedies of his own choosing, and he asked about opium drops offered by a friend, of unknown strength. The state prescription monitoring program shows no controlled prescriptions. A small supply of a short-acting opioid at the lowest dose, with naloxone and clear limits, is safer than unmeasured drops from others. **S**
   - Acetaminophen 1 g three times a day on a schedule (3 g a day at most).
   - Oxycodone 2.5 mg (half a 5 mg tablet) only if pain is not relieved, no more than three doses a day; 15 tablets, no early refills, one prescriber.
   - Naloxone nasal spray in the house, with his assistant shown how to use it.
   - No alcohol on days he takes oxycodone, no sleeping pills, and no drops or remedies from anyone else; doses kept in a locked box.
   - Review in two weeks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count and kidney function before radiotherapy and before an opioid | Before treatment, then at each visit during treatment | Completed today | Hemoglobin 10.9 g/dL, white count 8.2, platelets 254; creatinine 1.22 mg/dL (eGFR 59), potassium 4.5 mmol/L |
| Laboratory | Urine culture from the sick visit | With symptoms of catheter-associated infection | Completed today | Escherichia coli sensitive to cefpodoxime; no change of antibiotic |
| Imaging | Staging: chest imaging and CT or MRI of the abdomen and pelvis | Before treatment of muscle-invasive bladder cancer | Completed today | CT urography and chest CT reviewed with the pathology: cT3b N0 M0; bone scan not needed without bone pain |
| Examination | Post-void residual after the trial without catheter | At baseline when retention is suspected, after a trial without catheter, and when symptoms change | Completed today | 140 mL after voiding 260 mL |
| Survey | IPSS | Baseline and at every follow-up visit (CMID BPH) | Completed today | 14, moderate, from 22 before the catheter |
| Survey | Pain intensity (0 to 10) | At every visit with cancer pain, and before and after any opioid | Completed today | 5 of 10, suprapubic |
| Examination | Geriatric assessment before cancer treatment (G8 screen, function, nutrition, comorbidity, social support) | Before choosing cancer treatment in adults 65 and older | Completed today | G8 11 of 17; independent in self-care, needs help with shopping and travel; BMI 18.5; lives with an assistant. Cognitive screen and Timed Up and Go are booked for the wellness visit next week |
| Medication safety | Opioid start: risk review, prescription monitoring program, naloxone, bowel regimen, lowest dose of an immediate-release opioid, and a follow-up date | At the start, then within 1 to 4 weeks | Completed today | Prescription monitoring program clear; no benzodiazepine or other sedative; naloxone and senna prescribed; oxycodone 2.5 mg as needed, 15 tablets; review in two weeks |
| Medication safety | Alpha-blocker tolerability | At each visit in a frail older adult | Completed today | No dizziness; blood pressure 124/68 mmHg |
| Referral | Radiation oncology and palliative care | When treatment is chosen | Referred | Planning scan and the first fraction next week; palliative care home visit within two weeks |
| Imaging | Bladder cancer surveillance schedule (cystoscopy and cytology for NMIBC; CT every 6 to 12 months after cystectomy) | Applies after NMIBC treatment or cystectomy | Not indicated | Neither applies: he has muscle-invasive disease treated with palliative-intent radiotherapy, so response is judged by symptoms, with cystoscopy or CT only if they would change care |

## Goal progress

- Find the cause of the bleeding within three weeks. Outcome by 1778-04-22: CT urography in two days, cystoscopy in one week, resection in nine days; pathology reviewed at sixteen days. **S**
- Relieve the retention and recover kidney function. Outcome by 1778-04-22: Creatinine 1.68 to 1.22 mg/dL; voiding after the trial without catheter with a residual of 140 mL. **S**
- Treatment that controls bleeding and local symptoms while keeping him at home and writing. In progress; target 1778-05-27. **S**
- Pain at or below 3 of 10 without sedation, falls, or constipation. In progress; target 1778-05-27. **S**
- A written plan for future care, with a named health care agent. In progress; target 1778-04-28. **S**

## Medication changes

- Started: Acetaminophen 500 mg oral tablet, two tablets by mouth three times daily (3 g a day) **S**
- Started: Oxycodone 5 mg oral tablet, one half tablet (2.5 mg) by mouth every 6 hours if needed for bladder pain not relieved by acetaminophen, no more than three doses a day; 15 tablets dispensed **S**
- Started: Sennosides 8.6 mg oral tablet, two tablets at bedtime while taking oxycodone **S**
- Started: Naloxone 4 mg nasal spray, one spray in one nostril for suspected opioid overdose; call 911; may repeat in 2 to 3 minutes in the other nostril **S**

## Guideline basis

- Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024) (2024), American Urological Association
- NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026), National Comprehensive Cancer Network
- EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer (2026), European Association of Urology
- Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment (Hafeez S, et al.) (2017), International Journal of Radiation Oncology, Biology, Physics
- Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023), American Urological Association
- Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America (2009), Infectious Diseases Society of America
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022), Centers for Disease Control and Prevention
- American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023), American Geriatrics Society
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology (2018), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026), Aether Forge

## Follow-up

- Wellness visit next week; chronic-care review in two weeks, on the day of the second radiotherapy fraction; call for a falling stream, clots, fever, or pain not controlled. **S**
- Next scheduled visit 1778-04-28: subsequent annual wellness visit at 83. **S**
